Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

NET 2Gastrointestinal 2Endocrine 2

Conditions

Neuroendocrine Tumors 102Thyroid Neoplasms 40Thyroid Cancer, Papillary 36Carcinoid Tumor 32Neoplasms 28Multiple Endocrine Neoplasia Type 1 22Adenocarcinoma, Follicular 22Thyroid Carcinoma, Anaplastic 21Neoplasm Metastasis 21Pituitary Neoplasms 20Carcinoma, Neuroendocrine 20Pheochromocytoma 19Carcinoma, Medullary 19Paraganglioma 17Carcinoma, Non-Small-Cell Lung 17Somatostatinoma 16Adrenocortical Carcinoma 16Pancreatic Neoplasms 14Carcinoma, Islet Cell 14Insulinoma 12Glucagonoma 12Adenoma, Islet Cell 12Gastrinoma 11Colorectal Neoplasms 11Breast Neoplasms 11Sarcoma 10Melanoma 10Gastro-enteropancreatic neuroendocrine tumor 10Carcinoma, Renal Cell 10Pituitary ACTH Hypersecretion 9

Interventions

Sunitinib 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Pancreatic Neuroendocrine Tumors × Endocrine × Clear all
NCT02842749 2025-02-10

Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China

Novartis

Phase 4 Completed
61 enrolled 9 charts
EndocrineGastrointestinalNET

Pancreatic Neuroendocrine Tumors

NCT02282059 2024-06-20

The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors

Pfizer

Completed
100 enrolled 13 charts
EndocrineGastrointestinalNET

Pancreatic Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡